antazoline has been researched along with Atrial Fibrillation in 17 studies
Antazoline: An antagonist of histamine H1 receptors.
antazoline : A member of the class of imidazolines that is 2-aminomethyl-2-imidazoline in which the exocyclic amino hydrogens are replaced by benzyl and phenyl groups. Antazoline is only found in individuals that have taken the drug.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to assess the clinical efficacy of antazoline, a first-generation anti-histaminic agent, in the rapid conversion of paroxysmal non-valvular atrial fibrillation (AF) to sinus rhythm in patients without heart failure." | 9.24 | Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study). ( Beckowski, M; Chwyczko, T; Dabrowski, R; Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Syska, P; Szwed, H; Wozniak, J, 2017) |
| "Background Antazoline mesylate represents an antihistamine capable of rapid and safe cardioversion of atrial fibrillation, yet evidence concerning its efficacy in comparison to other medications is insufficient." | 7.88 | Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study. ( Bula, K; Mizia-Stec, K; Wilkosz, K; Wróbel, W; Wrona, K; Wybraniec, MT, 2018) |
| "The antihistaminic antazoline (ANT) was reported to be highly effective and safe for rapid conversion of atrial fibrillation (AF)." | 7.85 | Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent. ( Bögeholz, N; Bogossian, H; Dechering, DG; Eckardt, L; Fehr, M; Frommeyer, G; Kaese, S; Milberg, P; Pott, C; Sterneberg, M, 2017) |
| "INTRODUCTION Numerous studies described the effectiveness and safety of antazoline in pharmacological cardioversion of short‑duration atrial fibrillation (AF)." | 7.83 | Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department. ( Farkowski, MM; Kowalik, I; Maciąg, A; Pytkowski, M; Sterliński, M; Szwed, H; Woźniak, J; Żurawska, M, 2016) |
| "To assess safety and efficacy of antazoline for termination of atrial fibrillation (AF) occurring during ablation of accessory pathways (AP)." | 7.80 | Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways. ( Baran, J; Futyma, P; Kryński, T; Kułakowski, P; Piotrowski, R; Stec, S, 2014) |
| "Antazoline is a first generation antihistaminic agent with chinidin-like properties." | 6.77 | Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study). ( Dabrowski, R; Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H, 2012) |
| "Antazoline has been shown to be effective and safe in various patient populations." | 5.72 | Rapid pharmacological cardioversion of recent-onset atrial fibrillation using antazoline in elderly patients. ( Farkowski, MM; Gardziejczyk, P; Kowalik, I; Kołakowski, K; Maciąg, A; Pytkowski, M; Szwed, H; Żurawska, M, 2022) |
| "Antazoline appears to be an efficacious agent for termination of AF in real‑world setting." | 5.72 | Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study). ( Balsam, P; Bula, K; Błaszczyk, R; Ceynowa-Sielawko, B; Ćwiek-Rębowska, E; Dembowski, T; Farkowski, M; Kasprzak, JD; Koziński, M; Krzowski, B; Maciąg, A; Miśkowiec, D; Mizia-Stec, K; Ozierański, K; Peller, M; Szołkiewicz, M; Szwed, H; Wańha, W; Wójcik, M; Wróbel, W; Wybraniec, MT, 2022) |
| "Antazoline is a first-generation antihistaminic drug used primarily in eye drop formulations." | 5.51 | Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venou ( Farkowski, MM; Konka, M; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H, 2019) |
| "Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness and, more importantly, safety in stable CAD patients, have been sparse." | 5.48 | Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department. ( Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H; Zurawska, M, 2018) |
| "Antazoline is an antihistaminic agent with antiarrhythmic properties." | 5.42 | Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation. ( Balsam, P; Grabowski, M; Kiliszek, M; Koźluk, E; Kołtowski, Ł; Lodziński, P; Opolski, G; Peller, M; Piątkowska, A, 2015) |
| "The aim of the study was to assess the clinical efficacy of antazoline, a first-generation anti-histaminic agent, in the rapid conversion of paroxysmal non-valvular atrial fibrillation (AF) to sinus rhythm in patients without heart failure." | 5.24 | Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study). ( Beckowski, M; Chwyczko, T; Dabrowski, R; Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Syska, P; Szwed, H; Wozniak, J, 2017) |
| "Background Antazoline mesylate represents an antihistamine capable of rapid and safe cardioversion of atrial fibrillation, yet evidence concerning its efficacy in comparison to other medications is insufficient." | 3.88 | Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study. ( Bula, K; Mizia-Stec, K; Wilkosz, K; Wróbel, W; Wrona, K; Wybraniec, MT, 2018) |
| "The antihistaminic antazoline (ANT) was reported to be highly effective and safe for rapid conversion of atrial fibrillation (AF)." | 3.85 | Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent. ( Bögeholz, N; Bogossian, H; Dechering, DG; Eckardt, L; Fehr, M; Frommeyer, G; Kaese, S; Milberg, P; Pott, C; Sterneberg, M, 2017) |
| "INTRODUCTION Numerous studies described the effectiveness and safety of antazoline in pharmacological cardioversion of short‑duration atrial fibrillation (AF)." | 3.83 | Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department. ( Farkowski, MM; Kowalik, I; Maciąg, A; Pytkowski, M; Sterliński, M; Szwed, H; Woźniak, J; Żurawska, M, 2016) |
| "To assess safety and efficacy of antazoline for termination of atrial fibrillation (AF) occurring during ablation of accessory pathways (AP)." | 3.80 | Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways. ( Baran, J; Futyma, P; Kryński, T; Kułakowski, P; Piotrowski, R; Stec, S, 2014) |
| "Antazoline is a first generation antihistaminic agent with chinidin-like properties." | 2.77 | Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study). ( Dabrowski, R; Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H, 2012) |
| "Antazoline has been shown to be effective and safe in various patient populations." | 1.72 | Rapid pharmacological cardioversion of recent-onset atrial fibrillation using antazoline in elderly patients. ( Farkowski, MM; Gardziejczyk, P; Kowalik, I; Kołakowski, K; Maciąg, A; Pytkowski, M; Szwed, H; Żurawska, M, 2022) |
| "Antazoline appears to be an efficacious agent for termination of AF in real‑world setting." | 1.72 | Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study). ( Balsam, P; Bula, K; Błaszczyk, R; Ceynowa-Sielawko, B; Ćwiek-Rębowska, E; Dembowski, T; Farkowski, M; Kasprzak, JD; Koziński, M; Krzowski, B; Maciąg, A; Miśkowiec, D; Mizia-Stec, K; Ozierański, K; Peller, M; Szołkiewicz, M; Szwed, H; Wańha, W; Wójcik, M; Wróbel, W; Wybraniec, MT, 2022) |
| "Antazoline is a first-generation antihistaminic drug used primarily in eye drop formulations." | 1.51 | Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venou ( Farkowski, MM; Konka, M; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H, 2019) |
| "Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness and, more importantly, safety in stable CAD patients, have been sparse." | 1.48 | Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department. ( Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H; Zurawska, M, 2018) |
| "Antazoline is an antihistaminic agent with antiarrhythmic properties." | 1.42 | Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation. ( Balsam, P; Grabowski, M; Kiliszek, M; Koźluk, E; Kołtowski, Ł; Lodziński, P; Opolski, G; Peller, M; Piątkowska, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Farkowski, MM | 7 |
| Maciąg, A | 8 |
| Żurawska, M | 3 |
| Kołakowski, K | 1 |
| Gardziejczyk, P | 1 |
| Kowalik, I | 6 |
| Szwed, H | 8 |
| Pytkowski, M | 6 |
| Wybraniec, MT | 3 |
| Miśkowiec, D | 2 |
| Ceynowa-Sielawko, B | 2 |
| Balsam, P | 3 |
| Wójcik, M | 2 |
| Wróbel, W | 3 |
| Farkowski, M | 1 |
| Ćwiek-Rębowska, E | 2 |
| Szołkiewicz, M | 2 |
| Ozierański, K | 2 |
| Błaszczyk, R | 2 |
| Bula, K | 3 |
| Dembowski, T | 2 |
| Peller, M | 3 |
| Krzowski, B | 2 |
| Wańha, W | 2 |
| Koziński, M | 2 |
| Kasprzak, JD | 2 |
| Mizia-Stec, K | 3 |
| Topp-Zielińska, A | 1 |
| Calvert, P | 1 |
| Gupta, D | 1 |
| Lip, GYH | 1 |
| Chwyczko, T | 1 |
| Beckowski, M | 1 |
| Syska, P | 1 |
| Wozniak, J | 2 |
| Dabrowski, R | 2 |
| Wilkosz, K | 1 |
| Wrona, K | 1 |
| Konka, M | 1 |
| Piotrowski, R | 1 |
| Kryński, T | 1 |
| Baran, J | 1 |
| Futyma, P | 1 |
| Stec, S | 1 |
| Kułakowski, P | 1 |
| Koźluk, E | 1 |
| Piątkowska, A | 1 |
| Lodziński, P | 1 |
| Kiliszek, M | 1 |
| Kołtowski, Ł | 1 |
| Grabowski, M | 1 |
| Opolski, G | 1 |
| Sterliński, M | 1 |
| Frommeyer, G | 1 |
| Sterneberg, M | 1 |
| Dechering, DG | 1 |
| Kaese, S | 1 |
| Bögeholz, N | 1 |
| Pott, C | 1 |
| Fehr, M | 1 |
| Bogossian, H | 1 |
| Milberg, P | 1 |
| Eckardt, L | 1 |
| KIGER, RG | 1 |
| REYNOLDS, EW | 1 |
| BAIRD, WM | 1 |
| CLIFFORD, ME | 1 |
| ACHRISTIANSEN, I | 1 |
| NISSEN, NI | 1 |
| THOMSEN, C | 1 |
| Adamski, M | 1 |
| Kontek, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Efficacy of Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation - a Single Centre, Randomized, Double-blind, Placebo-controlled Study (the AnPAF Study)[NCT01527279] | Phase 4 | 74 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for antazoline and Atrial Fibrillation
| Article | Year |
|---|---|
Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study).
Topics: Action Potentials; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antazoline; Anti-Arr | 2017 |
Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).
Topics: Adult; Aged; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Electroca | 2012 |
15 other studies available for antazoline and Atrial Fibrillation
| Article | Year |
|---|---|
Rapid pharmacological cardioversion of recent-onset atrial fibrillation using antazoline in elderly patients.
Topics: Aged; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Retros | 2022 |
Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study).
Topics: Aged; Amiodarone; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Fe | 2022 |
Pharmacological Cardioversion in Patients with Recent-Onset Atrial Fibrillation and Chronic Kidney Disease Subanalysis of the CANT II Study.
Topics: Amiodarone; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; | 2022 |
Antazoline: the Lazarus of antiarrhythmic drugs?
Topics: Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans | 2022 |
Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.
Topics: Aged; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Coronary Artery Disease; | 2018 |
Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study.
Topics: Aged; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Female; Hi | 2018 |
Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venou
Topics: Administration, Intravenous; Aged; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Cryosurg | 2019 |
Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways.
Topics: Accessory Atrioventricular Bundle; Adult; Antazoline; Atrial Fibrillation; Catheter Ablation; Dose-R | 2014 |
Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation.
Topics: Aged; Antazoline; Atrial Fibrillation; Catheter Ablation; Female; Humans; Male; Middle Aged; Pulmona | 2015 |
Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department.
Topics: Aged; Aged, 80 and over; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Emergency Service, | 2016 |
Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent.
Topics: Acetylcholine; Action Potentials; Animals; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2017 |
AN EVALUATION OF ANTAZOLINE AS AN ANTI-ARRHYTHMIC AGENT.
Topics: Antazoline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 1964 |
A CLINICAL TRIAL OF ANTAZOLINE IN THE TREATMENT OF ARRHYTHMIAS.
Topics: Antazoline; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; | 1964 |
[ANTAZOLINE IN CARDIAC ARRHYTHMIAS].
Topics: Antazoline; Arrhythmias, Cardiac; Atrial Fibrillation; Bundle-Branch Block; Cardiac Conduction Syste | 1965 |
[Drug treatment of auricular fibrillation].
Topics: Aged; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Digitalis Glycosides; Drug Therapy, C | 1981 |